Rockefeller Capital Management L.P. Purchases 22,559 Shares of Gilead Sciences, Inc. $GILD

Rockefeller Capital Management L.P. grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 34.0% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 88,893 shares of the biopharmaceutical company’s stock after purchasing an additional 22,559 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in Gilead Sciences were worth $10,911,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Brighton Jones LLC raised its position in Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after acquiring an additional 2,450 shares during the period. Bison Wealth LLC bought a new stake in shares of Gilead Sciences during the 4th quarter valued at $215,000. Sivia Capital Partners LLC increased its stake in shares of Gilead Sciences by 16.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock worth $464,000 after purchasing an additional 602 shares in the last quarter. Ieq Capital LLC increased its stake in shares of Gilead Sciences by 12.0% in the 2nd quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company’s stock worth $13,160,000 after purchasing an additional 12,705 shares in the last quarter. Finally, Diversify Advisory Services LLC raised its holdings in Gilead Sciences by 18.6% in the 2nd quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company’s stock worth $516,000 after purchasing an additional 674 shares during the period. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Up 0.1%

Shares of Gilead Sciences stock opened at $125.19 on Thursday. The company has a market capitalization of $155.43 billion, a P/E ratio of 17.06 and a beta of 0.31. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The company has a fifty day moving average of $130.76 and a 200 day moving average of $134.31. Gilead Sciences, Inc. has a fifty-two week low of $104.46 and a fifty-two week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. The business had revenue of $6.96 billion for the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business’s quarterly revenue was up 4.4% on a year-over-year basis. During the same period last year, the firm earned $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post -0.8 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be given a dividend of $0.82 per share. The ex-dividend date is Monday, June 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.6%. Gilead Sciences’s dividend payout ratio (DPR) is currently 44.69%.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $123.92, for a total transaction of $371,760.00. Following the sale, the insider owned 124,234 shares of the company’s stock, valued at approximately $15,395,077.28. This trade represents a 2.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $125.40, for a total value of $376,200.00. Following the completion of the transaction, the chief financial officer directly owned 171,646 shares in the company, valued at approximately $21,524,408.40. This represents a 1.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 68,000 shares of company stock worth $8,930,150. 0.30% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on GILD. Maxim Group upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price on the stock in a research report on Wednesday, May 20th. Citigroup upped their price target on Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 price objective on shares of Gilead Sciences in a research note on Tuesday, June 16th. Weiss Ratings cut Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, May 28th. Finally, Wall Street Zen downgraded Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Twenty-five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and an average price target of $158.41.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.